| [1] |
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11):825-830.
|
| [2] |
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association[J]. Circulation, 2019, 139(10):e56-e528.
|
| [3] |
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225):709-733.
|
| [4] |
Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease[J]. Circulation, 2013, 127(5):569-574.
|
| [5] |
Ding WY, Gupta D, Wong CF, et al. Pathophysiology of atrial fibrillation and chronic kidney disease[J]. Cardiovasc Res, 2021, 117(4):1046-1059.
|
| [6] |
Landray MJ, Wheeler DC, Lip GY, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study[J]. Am J Kidney Dis, 2004, 43(2):244-253.
|
| [7] |
Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation[J]. Circulation, 2001, 104(24):2886-2891.
|
| [8] |
Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease[J]. Pharmacol Rev, 2007, 59(3):251-287.
|
| [9] |
Goette A, Staack T, Röcken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation[J]. J Am Coll Cardiol, 2000, 35(6):1669-1677.
|
| [10] |
Heijman J, Voigt N, Ghezelbash S, et al. Calcium handling abnormalities as a target for atrial fibrillation therapeutics: how close to clinical implementation?[J]. J Cardiovasc Pharmacol, 2015, 66(6):515-522.
|
| [11] |
Chen WT, Chen YC, Hsieh MH, et al. The uremic toxin indoxyl sulfate increases pulmonary vein and atrial arrhythmogenesis[J]. J Cardiovasc Electrophysiol, 2015, 26(2):203-210.
|
| [12] |
Yamagami F, Tajiri K, Yumino D, et al. Uremic toxins and atrial fibrillation: mechanisms and therapeutic implications[J]. Toxins (Basel), 2019, 11(10):597.
|
| [13] |
Umana E, Ahmed W, Alpert MA. Valvular and perivalvular abnormalities in end-stage renal disease[J]. Am J Med Sci, 2003, 325(4):237-242.
|
| [14] |
Chen SC, Su HM, Hung CC, et al. Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease[J]. Clin J Am Soc Nephrol, 2011, 6(12):2750-2758.
|
| [15] |
Pisters R, Lane DA, Marin F, et al. Stroke and thromboembolism in atrial fibrillation[J]. Circ J, 2012, 76(10):2289-2304.
|
| [16] |
Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease[J]. N Engl J Med, 2012, 367(7):625-635.
|
| [17] |
Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study[J]. J Am Coll Cardiol, 2014, 64(23):2471-2482.
|
| [18] |
Yahalom G, Schwartz R, Schwammenthal Y, et al. Chronic kidney disease and clinical outcome in patients with acute stroke[J]. Stroke, 2009, 40(4):1296-1303.
|
| [19] |
Kerr KF, Wang Z, Janes H, et al. Net reclassification indices for evaluating risk prediction instruments: a critical review[J]. Epidemiology, 2014, 25(1):114-121.
|
| [20] |
Abumuaileq RR, Abu-Assi E, López-López A, et al. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation[J]. BMC Cardiovasc Disord, 2015, 15:156.
|
| [21] |
Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review[J]. Thromb Haemost, 2018, 118(12):2171-2187.
|
| [22] |
Huang KW, Leu HB, Luo JC, et al. Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis[J]. Dig Dis Sci, 2014, 59(4):807-813.
|
| [23] |
Zulkifly H, Lip GYH, Lane DA. Bleeding risk scores in atrial fibrillation and venous thromboembolism[J]. Am J Cardiol, 2017, 120(7):1139-1145.
|
| [24] |
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
|
| [25] |
Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K Anticoagulant Agents in patients with advanced chronic kidney disease or on dialysis with AF[J]. J Am Coll Cardiol, 2016, 67(24):2888-2899.
|
| [26] |
He W, Zhang H, Zhu W, et al. Effect of anticoagulation therapy in older patients with chronic kidney disease and atrial fibrillation: a meta-analysis[J]. Medicine (Baltimore), 2019, 98(42):e17628.
|
| [27] |
Yang F, Hellyer JA, Than C, et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease[J]. Heart, 2017, 103(11):818-826.
|
| [28] |
Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission?[J]. JAMA, 2014, 311(9):913-915.
|
| [29] |
Chan PH, Huang D, Yip PS, et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis[J]. Europace, 2016, 18(5):665-671.
|
| [30] |
Bai Y, Chen H, Yang Y, et al. Safety of antithrombotic drugs in patients with atrial fibrillation and non-end-stage chronic kidney disease: Meta-analysis and systematic review[J]. Thromb Res, 2016, 137:46-52.
|
| [31] |
Malhotra K, Ishfaq MF, Goyal N, et al. Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis[J]. Neurology, 2019, 92(21):e2421-e2431.
|
| [32] |
Siltari A, Vapaatalo H. Vascular calcification, vitamin K and warfarin therapy - possible or plausible connection? [J]. Basic Clin Pharmacol Toxicol, 2018, 122(1):19-24.
|
| [33] |
Chen J, Budoff MJ, Reilly MP, et al. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease[J]. JAMA Cardiol, 2017, 2(6):635-643.
|
| [34] |
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12):1139-1151.
|
| [35] |
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011, 365(10):883-891.
|
| [36] |
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11):981-992.
|
| [37] |
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013, 369(22):2093-2104.
|
| [38] |
Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of Apixaban compared with Warfarin in patients with atrial fibrillation in relation to renal function over time: Insights from the ARISTOTLE randomized clinical trial[J]. JAMA Cardiol, 2016, 1(4):451-460.
|
| [39] |
Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis[J]. Circulation, 2015, 131(11):972-979.
|
| [40] |
Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis[J]. Circulation, 2015, 131(11):972-979.
|
| [41] |
Kuno T, Takagi H, Ando T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis[J]. J Am Coll Cardiol, 2020, 75(3):273-285.
|
| [42] |
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons[J]. Circulation, 2019, 140(2):e125-e151.
|
| [43] |
Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF Trials[J]. J Am Coll Cardiol, 2017, 70(24):2964-2975.
|
| [44] |
Li M, Liu T, Luo D, et al. Systematic review and meta-analysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation[J]. Cardiol J, 2014, 21(1):89-95.
|
| [45] |
Boriani G, Savelieva I, Dan GA, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society[J]. Europace, 2015, 17(8):1169-1196.
|
| [46] |
Li M, Liu T, Luo D, Li G. Systematic review and meta-analysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation[J]. Cardiol J, 2014, 21(1):89-95.
|
| [47] |
王静, 沈尤美, 郦明芳,等. 肾功能不全对肺静脉前庭隔离术治疗阵发性心房颤动的影响[J].南京医科大学学报, 2019,(11):1605-1608.
|
| [48] |
Navaravong L, Barakat M, Burgon N, et al. Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2015, 26(1):21-27.
|
| [49] |
Diemberger I, Genovesi S, Massaro G, et al. Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease[J]. Curr Pharm Des, 2018, 24(24):2794-2801.
|